Compare RAIL & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAIL | CRBU |
|---|---|---|
| Founded | 1901 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.6M | 203.9M |
| IPO Year | 2005 | 2021 |
| Metric | RAIL | CRBU |
|---|---|---|
| Price | $13.50 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 139.4K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $559,425,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.34 | $5.37 |
| P/E Ratio | $8.65 | ★ N/A |
| Revenue Growth | ★ 56.22 | N/A |
| 52 Week Low | $4.31 | $0.66 |
| 52 Week High | $14.90 | $3.53 |
| Indicator | RAIL | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 54.54 |
| Support Level | $7.62 | $1.71 |
| Resistance Level | N/A | $2.11 |
| Average True Range (ATR) | 0.79 | 0.15 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 40.72 | 49.33 |
FreightCar America Inc is a manufacturer of railcars and components, serving diverse transportation needs in North America. The company designs and produces a wide range of railcar types, including box cars, hoppers, covered hoppers, gondolas, and flat cars for both intermodal and non-intermodal freight. The company has two segments: The Manufacturing segment encompasses new railcar manufacturing, used railcar sales, leasing, and rebuilds, while the Aftermarket segment includes the selling of forged, cast and fabricated railcar parts and supplies for all railcar types, and provides aftermarket services including safety training, railcar inspections, and preventative maintenance. The company's revenue is predominantly derived from its Manufacturing segment.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.